亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Association Between Intravenous Antihypertensives and Functional Outcome After Successful Endovascular Thrombectomy

医学 优势比 改良兰金量表 血压 冲程(发动机) 尼卡地平 麻醉 内科学 拉贝洛尔 外科 缺血性中风 机械工程 工程类 缺血
作者
Jae Wook Jung,Young Dae Kim,JoonNyung Heo,Hyungwoo Lee,Byung Moon Kim,Dong Joon Kim,Na‐Young Shin,Haram Joo,Bang‐Hoon Cho,Seong Hwan Ahn,Hyungjong Park,Sung‐Il Sohn,Jeong‐Ho Hong,Jaeseob Yun,Tae‐Jin Song,Yoonkyung Chang,Gyu Sik Kim,Kwon‐Duk Seo,Kijeong Lee,Jun Young Chang
出处
期刊:Stroke [Lippincott Williams & Wilkins]
标识
DOI:10.1161/strokeaha.125.051696
摘要

BACKGROUND: Intravenous antihypertensives are frequently used to control blood pressure after successful endovascular thrombectomy (EVT), yet studies investigating the relationship between intravenous antihypertensive use and functional outcomes after successful EVT remain limited. METHODS: We conducted an exploratory secondary analysis of the OPTIMAL-BP trial (Outcome in Patients Treated With Intra-Arterial Thrombectomy–Optimal Blood Pressure Control), which compared intensive (systolic blood pressure <140 mm Hg) versus conventional blood pressure management (systolic blood pressure, 140–180 mm Hg) within the first 24 hours after successful recanalization across 19 stroke centers in South Korea between June 2020 and November 2022. Patients were classified according to the administration of intravenous antihypertensives within the initial 24 hours after enrollment. The primary efficacy outcome was functional independence (modified Rankin Scale score of 0–2) at 3 months. RESULTS: Of the 302 patients (median, 75 years; 180 [59.6%] men), 141 (46.7%) received intravenous antihypertensives within the first 24 hours after EVT. Among the 141 patients who received intravenous antihypertensives, 133 (94.3%) were treated with nicardipine, 10 (7.0%) received labetalol, and 2 (1.4%) were administered both drugs. Patients who received intravenous antihypertensives had significantly lower rates of functional independence at 3 months (adjusted odds ratio, 0.51 [95% CI, 0.27–0.95]; P =0.035) and excellent neurological recovery at 24 hours (adjusted odds ratio, 0.46 [95% CI, 0.22–0.94]; P =0.036), as well as higher stroke-related mortality rates (adjusted odds ratio, 4.21 [95% CI, 1.24–16.4]; P =0.027), compared with patients who did not receive intravenous antihypertensives. Symptomatic intracerebral hemorrhage was not significantly different between groups (adjusted odds ratio, 1.67 [95% CI, 0.68–4.19]; P =0.267). CONCLUSIONS: The use of intravenous antihypertensives within the first 24 hours after successful EVT was associated with worse functional outcomes at 3 months. This finding highlights the need for a cautious assessment of the risks and benefits of administering intravenous antihypertensives immediately after EVT. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04205305.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
enen完成签到 ,获得积分10
1秒前
11秒前
树妖三三完成签到,获得积分10
18秒前
Orange应助张艳鑫采纳,获得30
23秒前
orbitvox发布了新的文献求助10
24秒前
Rn完成签到 ,获得积分0
26秒前
友好胜完成签到 ,获得积分10
35秒前
行悟完成签到 ,获得积分10
40秒前
41秒前
43秒前
芒果应助kiki采纳,获得10
44秒前
蓝宝宝发布了新的文献求助10
46秒前
Delire发布了新的文献求助30
48秒前
宝贝丫头完成签到 ,获得积分10
52秒前
54秒前
54秒前
小二郎应助科研通管家采纳,获得10
56秒前
56秒前
Jasper应助科研通管家采纳,获得80
56秒前
guigui发布了新的文献求助10
59秒前
所所应助guigui采纳,获得10
1分钟前
1分钟前
1分钟前
哆啦A梦完成签到 ,获得积分10
1分钟前
1分钟前
Ldq完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
追风少年完成签到,获得积分10
1分钟前
opus17完成签到,获得积分10
1分钟前
1分钟前
Delire完成签到,获得积分10
1分钟前
1分钟前
林JJ的小可爱完成签到,获得积分10
1分钟前
1分钟前
1分钟前
GXP发布了新的文献求助10
2分钟前
2分钟前
nihao完成签到 ,获得积分10
2分钟前
Shyee完成签到 ,获得积分10
2分钟前
Charles完成签到,获得积分10
2分钟前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Hydrothermal Circulation and Seawater Chemistry: Links and Feedbacks 1200
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5147958
求助须知:如何正确求助?哪些是违规求助? 4344356
关于积分的说明 13529461
捐赠科研通 4186258
什么是DOI,文献DOI怎么找? 2295559
邀请新用户注册赠送积分活动 1295928
关于科研通互助平台的介绍 1239574